Groundbreaking topline results demonstrated sensitivity for colorectal cancer of 92% with specificity of 90% and best-in-class sensitivity for advanced adenoma of 82%690 subjects analyzed including.
Issuer: Mainz BioMed N.V. / Key word(s): Study results25.04.2024 / 15:29 CET/CESTThe issuer is solely responsible for the content of this announcement.Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Cli.
Groundbreaking topline results demonstrated sensitivity for colorectal cancer of 92% with specificity of 90% and best-in-class sensitivity for advanced adenoma of 82%690 subjects analyzed including previously unexamined and reported patients